PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31259152-14	2019	Meanwhile, the downregulation of MyD88 through the overexpression of miR-149-5p or UA treatment inhibited the activation of the Akt signaling pathway in 231/PTX cells.	Paclitaxel	157-160	myeloid differentiation primary response gene 88	Mus musculus	33-38	
31259152-15	2019	Thus, our data indicate that UA can reverse PTX resistance by targeting the miRNA-149-5p/MyD88 axis in breast cancer cells.	Paclitaxel	44-47	myeloid differentiation primary response gene 88	Mus musculus	89-94	
31259152-0	2019	Ursolic Acid Reverses the Chemoresistance of Breast Cancer Cells to Paclitaxel by Targeting MiRNA-149-5p/MyD88.	Paclitaxel	68-78	myeloid differentiation primary response gene 88	Mus musculus	105-110	
31259152-4	2019	The role of miRNA-149-5p/MyD88 in the regulation of PTX resistance was investigated by the transfection of breast cancer cells with MDA-MB-231 (231) and MDA-MB-231/PTX-resistance (231/PTX) with lentiviruses carrying the MyD88 gene, shRNA specific for MyD88, the miR-149-5p gene, and shRNA specific for miR-149-5p.	Paclitaxel	52-55	myeloid differentiation primary response gene 88	Mus musculus	25-30	
24573741-0	2014	Paclitaxel-exposed ovarian cancer cells induce cancer-specific CD4+ T cells after doxorubicin exposure through regulation of MyD88 expression.	Paclitaxel	0-10	myeloid differentiation primary response gene 88	Mus musculus	125-130	
24573741-6	2014	We also observed that in paclitaxel-exposed MOSECs treated with doxorubicin, but not cisplatin, the expression of MyD88 and related target proteins decreased compared to paclitaxel-exposed MOSECs only, while in BMDCs co-cultured with these MOSECs the expression of myeloid differentiation primary response gene 88 (MyD88) increased.	Paclitaxel	25-35	myeloid differentiation primary response gene 88	Mus musculus	114-119	
24573741-6	2014	We also observed that in paclitaxel-exposed MOSECs treated with doxorubicin, but not cisplatin, the expression of MyD88 and related target proteins decreased compared to paclitaxel-exposed MOSECs only, while in BMDCs co-cultured with these MOSECs the expression of myeloid differentiation primary response gene 88 (MyD88) increased.	Paclitaxel	25-35	myeloid differentiation primary response gene 88	Mus musculus	315-320	
24573741-6	2014	We also observed that in paclitaxel-exposed MOSECs treated with doxorubicin, but not cisplatin, the expression of MyD88 and related target proteins decreased compared to paclitaxel-exposed MOSECs only, while in BMDCs co-cultured with these MOSECs the expression of myeloid differentiation primary response gene 88 (MyD88) increased.	Paclitaxel	170-180	myeloid differentiation primary response gene 88	Mus musculus	114-119	
11500829-0	2001	The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol.	Paclitaxel	58-63	myeloid differentiation primary response gene 88	Mus musculus	12-17	
11500829-5	2001	Taxol-induced NF-kappa B-driven luciferase activity was reduced after transfection of RAW 264.7 macrophages with a dominant negative version of mouse MyD88.	Paclitaxel	0-5	myeloid differentiation primary response gene 88	Mus musculus	150-155	
11500829-6	2001	Taxol-induced microtubule-associated protein kinase (MAPK) activation and NF-kappa B nuclear translocation were absent from TLR4-null macrophages, but were preserved in MyD88 knockout macrophages with a slight delay in kinetics.	Paclitaxel	0-5	myeloid differentiation primary response gene 88	Mus musculus	169-174	
11500829-8	2001	These results suggest that Taxol and LPS not only share a TLR4/MyD88-dependent pathway in generating inflammatory mediators, but also share a TLR4-dependent/MyD88-independent pathway leading to activation of MAPK and NF-kappa B.	Paclitaxel	27-32	myeloid differentiation primary response gene 88	Mus musculus	63-68	
11500829-8	2001	These results suggest that Taxol and LPS not only share a TLR4/MyD88-dependent pathway in generating inflammatory mediators, but also share a TLR4-dependent/MyD88-independent pathway leading to activation of MAPK and NF-kappa B.	Paclitaxel	27-32	myeloid differentiation primary response gene 88	Mus musculus	157-162